Active	Status	Sponsor type	Region	Phase	Filter
40 Active 7 Inactive 47 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

40 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Garza, Richard De La
NCT03787628: Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder	Completed	2	35	US	Cannabidiol (CBD) 600 mg, Placebo	University of California, Los Angeles, National Institute on Drug Abuse (NIDA)	Opioid-use Disorder	03/24	03/24
Kernen, Kenneth
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent	Terminated	3	105	US	VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga	Veru Inc.	Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer	05/23	05/23
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Active, not recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Nelson, Amy
NCT06186765: F15 Recharge Free Axonics SNM System Clinical Study	Recruiting	N/A	130	Europe, US	Axonics SNM System (Model 4101)	Axonics, Inc.	Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)	03/25	06/26
NCT06217328: RESTORE: An RCT to Evaluate the Efficacy of the Revi System	Recruiting	N/A	150	US	Revi System Treatment, Revi System - Delayed Activation	BlueWind Medical	Urinary Urge Incontinence	05/26	05/27
APEX, NCT06560476: OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH	Recruiting	N/A	500	US	Data collection	Urotronic Inc.	Benign Prostatic Hyperplasia	03/27	03/27
ESSENCE, NCT05882318: Effectiveness of eCoin at Sensory and Subsensory Amplitudes	Completed	N/A	47	US	eCoin Peripheral Neurostimulator System	Valencia Technologies Corporation	Urge Incontinence	04/24	05/24
PROGECT, NCT02302742: Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry	Recruiting	N/A	1500	US		University of Kansas Medical Center	Breast Cancer, Hereditary Breast and Ovarian Cancer	12/24	12/25
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer	Not yet recruiting	N/A	280	Europe, Canada, US, RoW	Aquablation Therapy, Radical Prostatectomy	PROCEPT BioRobotics	Localized Prostate Cancer	07/27	01/37
NCT02577302: CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology	Recruiting	N/A	200	US	CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System	Uro Medical Corporation	Urinary Incontinence, Urge	10/25	10/25
Osterhout, Danielle
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Active, not recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Mazzarella, Brian
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
NCT06567743: Brief Title: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC	Recruiting	2	50	US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	High-Risk Non-Muscle-Invasive Bladder Cancer	03/27	12/27
BREEZE, NCT04987138: Safety and Effectiveness Study of the Zenflow Spring System	Active, not recruiting	N/A	279	US	Zenflow Spring System, Sham Procedure, Foley Catheter	Zenflow, Inc.	BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)	06/24	06/26
NCT05010759: Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer	Terminated	N/A	3	US	NanoTherm Ablation	MagForce USA	Prostate Cancer	07/23	07/23
NCT05186740: ProVee Urethral Expander System IDE Study (ProVIDE)	Active, not recruiting	N/A	225	Europe, Canada, US	ProVee Urethral Expander System, ProVee Expander, ProVee, Urethral Access Sheath	ProVerum Medical	Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms	03/24	12/28
NCT06236802: ProVIDE II Bridging Study	Active, not recruiting	N/A	40	Europe, US	ProVee device, ProVee Expander, ProVee	ProVerum Medical	BPH With Symptomatic Lower Urinary Tract Symptoms	09/24	06/29
CLEAR, NCT04338776: Comparing UroLift Experience Against Rezūm	Recruiting	N/A	120	Europe, US	UroLift, Rezum	NeoTract, Inc.	Benign Prostatic Hyperplasia	05/25	12/25
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer	Not yet recruiting	N/A	280	Europe, Canada, US, RoW	Aquablation Therapy, Radical Prostatectomy	PROCEPT BioRobotics	Localized Prostate Cancer	07/27	01/37
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Active, not recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Rosenberg, Bradley
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Active, not recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Talaty, Pooja
NCT06062875: Effects of TNF Blockade on Human BPH/LUTS	Recruiting	2	70	US	Adalimumab, Placebo will be administered subcutaneously every 2 weeks, for a total of 6 injections.	NorthShore University HealthSystem, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Benign Prostatic Hyperplasia (BPH)	04/28	06/28
PRESERVE, NCT04972097: Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue	Active, not recruiting	N/A	121	US	Irreversible Electroporation, The NanoKnife System	Angiodynamics, Inc.	Prostate Cancer	07/24	07/24
GenBx, NCT05295407: Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy	Recruiting	N/A	1000	US	Genetic Assessment	NorthShore University HealthSystem, Northwestern University, Johns Hopkins University, GoPath Diagnostics	Prostate Cancer	12/24	12/25
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer	Not yet recruiting	N/A	280	Europe, Canada, US, RoW	Aquablation Therapy, Radical Prostatectomy	PROCEPT BioRobotics	Localized Prostate Cancer	07/27	01/37
NCT06054867: PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System	Active, not recruiting	N/A	22	US	Robotic Waterjet Treatment, Aquablation therapy	PROCEPT BioRobotics	Localized Prostate Cancer	04/25	04/25
NCT06051942: PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs	Recruiting	N/A	125	US, RoW	Robotic Waterjet Treatment, Aquablation therapy	PROCEPT BioRobotics	Benign Prostatic Hyperplasia, Localized Prostate Cancer	08/25	05/26
NCT05898932: Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes	Recruiting	N/A	300	US	Medical Management, Surgical Management	Northwestern University, NorthShore University HealthSystem, University of Chicago	Benign Prostatic Hyperplasia	08/26	08/26
NCT05608694: MRI Screening in Men at High Risk of Developing Prostate Cancer	Recruiting	N/A	250	US	Prostate MRI	University of Chicago	Prostate Cancer Screening	03/37	03/39
Penshorn, Jennifer
NCT05010759: Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer	Terminated	N/A	3	US	NanoTherm Ablation	MagForce USA	Prostate Cancer	07/23	07/23
NCT06051942: PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs	Recruiting	N/A	125	US, RoW	Robotic Waterjet Treatment, Aquablation therapy	PROCEPT BioRobotics	Benign Prostatic Hyperplasia, Localized Prostate Cancer	08/25	05/26
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Active, not recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Penshom, Jennifer
NCT04232696: Neuspera's Implantable Sacral Nerve Stimulation System in Patients with Symptoms of Urinary Urgency Incontinence (UUI)	Active, not recruiting	N/A	242	Europe, US	Neuspera Implantable Sacral Nerve Stimulation System	Neuspera Medical, Inc.	Urinary Urgency Incontinence	07/24	12/26
Twedt, Maressa
NCT06190197: Prophylactic Antibiotics in Cystectomy With Diversion	Recruiting	1	120	US	Prophylactic antibiotics postoperatively.	University of Minnesota	Muscle-Invasive Bladder Carcinoma, Radical Cystectomy, Ileal Conduit, Neobladder Diversion	10/26	10/26
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Active, not recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
BLCCR, NCT02660645: Blue Light Cystoscopy With Cysview® Registry	Recruiting	N/A	4400	US	Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system	Photocure, Catalyst Pharmaceutical Research	Bladder Cancer	12/28	12/28
Sesoko, Channing
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Active, not recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29